Price (delayed)
$18.38
Market cap
$39.93M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.07
Enterprise value
$45.02M
Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on its proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes its proprietary
There are no recent dividends present for XCUR.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.